| Oct 14 |
Inventiva secures up to $380m for MASH treatment lanifibranor
|
| Oct 14 |
Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?
|
| Oct 14 |
Inventiva secures financing of up to €348M to advance the Nativ3 phase 3 MASH study
|
| Oct 14 |
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
|
| Oct 14 |
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
|
| Oct 1 |
Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
| Sep 25 |
Inventiva S.A GAAP EPS of -€0.94 beats by €0.34, revenue of €0.04M misses by €1.46M
|
| Sep 25 |
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results
|
| Jul 31 |
Inventiva reports preliminary HI 2024 data
|
| Jul 31 |
Inventiva Reports Preliminary 2024 First-Half Financial Information¹
|
